MONROE TOWNSHIP, N.J., Dec. 2, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, ...
MONROE TOWNSHIP, NJ — Bracco Diagnostics has announced that the Food and Drug Administration has removed from the label of Lumason the contraindication that it should not be used in patients with ...
MONROE TOWNSHIP, N.J., July 15, 2019 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, ...
Lumason is supplied as a 3-part step-saving procedural kit. Each kit contains a Lumason vial containing 25 mg of lipid-type A lyophilized powder with headspace filled with 60.7 mg sulfur hexafluoride ...
PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that the results of a ...
WASHINGTON, DC — The US Food and Drug Administration has approved a new microbubble contrast agent for echocardiography: Lumason (Bracco Diagnostics) sulfur-hexafluoride lipid microspheres, announced ...
The Food and Drug Administration (FDA) has approved Lumason (sulfur hexafluoride lipid-type A microspheres; Bracco Diagnostics Inc.), an ultrasound enhancing agent, for use in echocardiography to ...
MONROE TOWNSHIP, N.J.--(BUSINESS WIRE)--Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A. - a global leading company in the diagnostic imaging business - today announced that the U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results